A 67-year-old male was referred for valve-in-valve (VIV) transcatheter aortic valve implantation (TAVI) in view of symptomatic, severe structural valve deterioration of a 23 mm Perimount 2800 (Edwards Lifesciences, USA) implanted 12 years earlier due to a severely stenotic bicuspid aortic valve. Latest transthoracic echocardiography showed a mean trans-prosthetic gradient of 80 mmHg, but no regurgitation. Pre-procedural computed tomography (CT) revealed adequate virtual valve-to-coronary distances (> 4 mm) (Figure 1A). The patient was scheduled for VIV-TAVI with a 25 mm Navitor™ (Abbott, USA) under local anesthesia. Compared to the Portico™ system (Abbott, USA), this latest-generation Navitor™ transcatheter heart valve (THV; Figure 1B) has an active outer NaviSeal™ cuff to prevent paravalvular leakage (PVL), optimized radial force, and a curved aortic outflow part to mitigate risk of aortic injury.
As a public service to our readership, this article - peer reviewed by the Editors of EuroIntervention and external reviewers - has been published immediately upon acceptance as it was received in the last round of revision. The content of this article is the responsibility of the authors.
Please note that supplementary movies are not available online at this stage. Once a paper is published in its edited and formatted form, it will be accompanied online by any supplementary movies.
To read the full content of this article, please log in to download the PDF.
Sign in to read and download the full articleForgot your password?
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com